J Cancer Res Clin Oncol:老年人去势难治性前列腺癌治疗计划意外终止风险因素研究

2018-01-08 AlexYang MedSci原创

最近,有研究人员进行了旨在确定患有去势难治性前列腺癌(CRPC)老年人中治疗计划中断相关的风险因素。该前瞻性群体研究包括了年龄≥70岁的且患有CRPC的病人,这些病人均为新进行治疗的病人。研究人员在基线对参与者进行了老年人身心健康评估(CGA),包括了伴随疾病、移动性和功能/精神/营养状态以及抑郁。更进一步的是,研究人员对疼痛密度、生活质量和ECOG表现状态以及医生的和病人的健康观点进行了记录,并

最近,有研究人员进行了旨在确定患有去势难治性前列腺癌(CRPC)老年人中治疗计划中断相关的风险因素。该前瞻性群体研究包括了年龄≥70岁的且患有CRPC的病人,这些病人均为新进行治疗的病人。研究人员在基线对参与者进行了老年人身心健康评估(CGA),包括了伴随疾病、移动性和功能/精神/营养状态以及抑郁。更进一步的是,研究人员对疼痛密度、生活质量和ECOG表现状态以及医生的和病人的健康观点进行了记录,并通过单变量和多变量分析对计划治疗的中断相关原因和因素进行了分析。

研究总共包括了160名符合研究的病人。平均年龄为77.5岁,其中,46%的病人接受了化疗,54%的病人接受了激素治疗。在91名病人中发生了计划治疗的中断。主要原因是疾病的恶化/死亡(63%)、副作用/毒性(22%)和治疗协议的撤销(8%)。在双变量分析中,与治疗中断相关的因素为年龄≥80岁、ECOG PS≥2、不良的健康状态(医生/病人的评估)和不良的功能和营养状态。在多变量分析中,与计划治疗中断相关的唯一剩下的因素为日常生活活动的破坏(ADL<100 points)(中断OR=4.2;p<0.05)。

最后,研究人员指出,他们的研究阐释了计划治疗的中断是常见的现象,ADL可能是CRPC老年患者治疗失败的一个显著的风险因素。

原始出处:


本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865266, encodeId=74771865266f1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Nov 03 22:03:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083202, encodeId=d79020832020d, content=<a href='/topic/show?id=d00064e0169' target=_blank style='color:#2F92EE;'>#治疗计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64701, encryptionId=d00064e0169, topicName=治疗计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 23 10:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283451, encodeId=85b6283451f7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jan 30 08:16:08 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528440, encodeId=8f99152844070, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jan 10 14:03:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276731, encodeId=ab7e2e673143, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jan 08 23:45:54 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-11-03 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865266, encodeId=74771865266f1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Nov 03 22:03:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083202, encodeId=d79020832020d, content=<a href='/topic/show?id=d00064e0169' target=_blank style='color:#2F92EE;'>#治疗计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64701, encryptionId=d00064e0169, topicName=治疗计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 23 10:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283451, encodeId=85b6283451f7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jan 30 08:16:08 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528440, encodeId=8f99152844070, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jan 10 14:03:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276731, encodeId=ab7e2e673143, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jan 08 23:45:54 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865266, encodeId=74771865266f1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Nov 03 22:03:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083202, encodeId=d79020832020d, content=<a href='/topic/show?id=d00064e0169' target=_blank style='color:#2F92EE;'>#治疗计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64701, encryptionId=d00064e0169, topicName=治疗计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 23 10:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283451, encodeId=85b6283451f7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jan 30 08:16:08 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528440, encodeId=8f99152844070, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jan 10 14:03:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276731, encodeId=ab7e2e673143, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jan 08 23:45:54 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-30 一个字-牛

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1865266, encodeId=74771865266f1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Nov 03 22:03:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083202, encodeId=d79020832020d, content=<a href='/topic/show?id=d00064e0169' target=_blank style='color:#2F92EE;'>#治疗计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64701, encryptionId=d00064e0169, topicName=治疗计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 23 10:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283451, encodeId=85b6283451f7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jan 30 08:16:08 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528440, encodeId=8f99152844070, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jan 10 14:03:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276731, encodeId=ab7e2e673143, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jan 08 23:45:54 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-10 freve
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865266, encodeId=74771865266f1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Nov 03 22:03:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083202, encodeId=d79020832020d, content=<a href='/topic/show?id=d00064e0169' target=_blank style='color:#2F92EE;'>#治疗计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64701, encryptionId=d00064e0169, topicName=治疗计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Oct 23 10:03:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283451, encodeId=85b6283451f7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jan 30 08:16:08 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528440, encodeId=8f99152844070, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jan 10 14:03:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276731, encodeId=ab7e2e673143, content=谢谢.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jan 08 23:45:54 CST 2018, time=2018-01-08, status=1, ipAttribution=)]
    2018-01-08 清风拂面

    谢谢.学习受益匪浅

    0

相关威廉亚洲官网

Oncogene:组蛋白甲基转移酶KMT2D能够通过表观激活LIFR和KLF4来维持前列腺癌的形成和转移

表观修饰因子的异常在前列腺癌(PCa)中越来越成为促进其形成的因素。组蛋白甲基转移酶KMT2D在各种各样肿瘤中常常出现作为异常的修饰因子,并且在PCa中的角色仍旧未知。更多的是,在中国病人中KMT2D的变异和它的下游信号途径以及靶标所知甚少。最近,有研究人员通过利用靶向疾病的测序,分析了32个与PCa显著相关的基因的突变谱,发现KMT2D在中国病人中高度变异(63.04%,29/46)。更多的是,

Sci Rep:在去势难治性前列腺癌中,AURKA的表达受雄激素调控

虽然第二代内分泌治疗显著的改善了生存,但是去势难治性前列腺癌(CRPC)细胞最终还是会逃避目前可以用的激素治疗,起因是雄激素受体(AR)信号的重新激活。因此,有研究人员指出,对新的、非经典的和可成药AR靶标基因的鉴定也许能够为治疗CRPC提供新的方法。之前的分析表明了Aurora kinase A(激光激酶A)(AURKA)在前列腺癌细胞中受雄激素调控,并且在AR中具有很高的表达水平。最近,有研究

盘点:近期前列腺癌研究进展盘点

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常williamhill asia 所说的前列腺癌就是指前列腺腺癌。williamhill asia 医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1】Clin Cancer Res:膀胱癌中BMP4可诱导M2巨噬细胞极

Prostate Cancer P D:高风险前列腺癌病人的结合新辅助雄激素阻断前列腺切除术后结果分析

患有高风险前列腺癌的病人在根治性前列腺切除术(RP)后,经历复发的可能性增加。之前,有研究人员在RP之前也进行了3次新辅助雄激素阻断治疗(ADT)试验,并且是在不利的中度和高风险前列腺癌中进行。最近,有研究人员报道了RP后病人的治疗效果情况。研究人员对病人进行了汇总分析,这些病人具有可利用的跟踪调查数据,并且是在3个机构中利用3种新辅助疗法进行治疗的。所有的病人在RP之前接受高强度的ADT。主要的

PLoS One:积极监控前列腺癌病人的重复多参数MRI分析

最近,有研究人员在积极监控(AS)的前列腺癌病人(PCa)中,对重复多参数MRI(mpMRI)发生的变化情况进行了研究和阐述,并且研究了mpMRI相关的参数在预测前列腺活检(Bx)格林森得分(GS)升级>3+3和基于方法的治疗变化(TC)之间的关系。研究包括了76名AS病人,并且为GS 3+3 PCa,并且在2006年到2015年之间对前列腺至少进行2次连续的mpMRIs。研究人员根据前列腺

Cancer Manag Res:意大利前列腺癌治疗的经济负担研究

在意大利,前列腺癌(PCa)在最近50年占据了所有癌症数目的20%。大多数病人在最初的诊断时是局部前列腺癌,但是许多病人在治疗后都发展为了复发性转移疾病。雄激素阻断疗法是治疗转移性PCa病人的标准李爱哦发,不幸的是,他们中的大多数在治疗5年内会发展成为去势难治性前列腺癌(CRPC)。转移性CRPC(mCRPC)严重的影响到了病人的生活质量,副作用和生存,并且会造成很大的经济花费。最近些年新的有效药